Virologic and Immunologic Effectiveness of Tipranavir/Ritonavir (TPV/r)- Versus Darunavir/Ritonavir (DRV/r)-Based Regimens in Clinical Practice

Abstract

Background: Although both tipranavir and darunavir are important options for the management of patients with multidrug resistant HIV, there are at present no studies comparing the effectiveness and safety of these 2 antiretroviral drugs in this population of patients. Objective: To compare the effectiveness and safety of ritonavir (TPV/r)- and darunavir/ritonavir (DRV/ r)-based therapies in treatment-experienced patients (n = 38 and 47, respectively). Methods: Multicenter, retrospective cohort study. Results: The median baseline viral load and CD4 count were 4.7 copies/mL (interquartile range [IQR] 4.3, 5.2) and 168 cells/mm³ (IQR 80, 252) for TPV/r patients and 4.7 copies/mL (IQR 3.7, 5.1) and 171 cells/mm³ (IQR 92, 290) for DRV/r patients. The median number of years on antiretroviral therapy (ART) prior to starting DRV/r or TPV/r were 12.7 (10.2-15.5) and 10.5 (8.4-12.6), respectively (P < .01). Current raltegravir (RAL) use (odds ratio [OR] 5.53, 95% CI 1.08-28.34) was significantly associated with virologic suppression at week 24 in multivariable logistic regression models, whereas the use of TPV/r was not significantly associated with virologic suppression compared to DRV/r (OR 0.93, 95% CI 0.27-3.18, P = .91). Conclusion: No significant difference was observed between DRV/r and TPV/r in terms of virologic suppression.

Keywords

HIV protease inhibitors highly active antiretroviral therapy anti-HIV drugs retrospective studies

References

Palella FJ, Jr , Delaney KM , Moorman AC , et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853-860.

Hogg RS , Yip B. , Kully C. , Craib KJ , O’Shaughnessy MV , Schechter MT , Montaner JS Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ. 1999;160(5):659-665.

Harris M. , Montaner JS Management of HIV-infected patients with multidrug-resistant virus. Curr HIV/AIDS Rep. 2004;1(3): 116-121.

Boccara F. Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors. AIDS. 2008;22(suppl 3):S19-S26.

Robertson SM , Penzak SR , Pau A. Drug interactions in the management of HIV infection: an update. Expert Opin Pharmacother. 2007;8(17):2947-2963.

Poppe SM , Slade DE , Chong KT , et al. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother. 1997;41(5):1058-1063.

De Meyer S. , Azijn H. , Surleraux D. , et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother . 2005;49(6):2314-2321.

Hicks CB , Cahn P. , Cooper DA , et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. 2006;368(9534): 466-475.

Clotet B. , Bellos N. , Molina JM , et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369(9568): 1169-1178.

10.

AIDS Clinical Trials Group. Table of grading severity of adult adverse experiences. Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, MD. 2004.

11.

Hall DB , Scherer J. , Schapiro J. , et al. Genotypic relationships between tipranavir and darunavir resistance in protease-inhibitor-experienced patients. Antivir Ther. 2007;12(suppl 1):S88.

12.

Markowitz M. , Nguyen BY , Gotuzzo E. , et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007;46(2):125-133.

13.

Saberi P. , Caswell NH , Gruta CI , Tokumoto JN , Dong BJ Immunologic benefits of enfuvirtide in patients enrolled in a drug assistance program. Ann Pharmacother. 2008;42(5):621-626.

14.

Viard JP , Fagard C. , Chaix ML , et al. Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients. AIDS. 2009;23(11):1383-1388.

15.

Svicher V. , Aquaro S. , D’Arrigo R. , et al. Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure. J Infect Dis. 2008;197(10):1408-1418.

16.

Hill A. , Moyle G. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials. HIV Med. 2007;8(8):259-264.